The prognostic significance of programmed cell death protein 1 and its ligand on lymphoma cells and tumor-immune cells in diffuse large B-cell lymphoma, not otherwise specified
Radiology and Oncology · 01.03.2024 · 58 (1) · 99-109
DOI: 10.2478/raon-2024-0010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Radiology and Oncology, online erschienen am 21.02.2024. Verfasst von Teja Cas Slak und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cytopathology, Institute of Oncology Ljubljana, Ljubljana, Slovenia. Hauptthemen laut MEDLINE: B7-H1 Antigen, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) is the most common type non-Hodgkin’s lymphoma, where the treatment of relapsed/refractory cases is the major challenge. Programmed cell death protein 1 (PD-1) and its ligand PD-L1 play a crucial role in the negative regulation of the immune response against the disease. The aim of the study was to analyze the expression of PD-1 and PD-L1 on lymphoma cells (LCs) and tumor-immune cells (TICs) and to investigate their correlation with outcome. Patients and methods Samples from 283 patients diagnosed with DLBCL, NOS (both germinal center B cell like [GCB] and non-GCB subtypes) were included in the study. Expression of PD-1 and PD-L1 was determined using double immunohistochemical staining (D-IHC) for PD-1/PAX5 and PD-L1/PAX5 on tissue microarrays. LCs were highlighted by D-IHC to obtain more accurate results. Clinical data and histologic diagnoses were obtained from electronic data records. We correlated clinical characteristics, and PD-1 and PD-L1 expression on LCs and TICs with progression-free survival (PFS) and overall survival (OS).
Results
Expression of PD-1 on TICs was observed in 38.4% and on LCs in 8.8% of cases, while PD-L1 was expressed on TICs in 46.8% and on LCs in 6.5% of cases. PD-L1 expression on LCs was more frequent in non-GCB subtype (p = 0.047). In addition, patients with PD-L1 expression on LCs had significantly shorter PFS (p = 0.015), and the expression retained significant in the multivariate model (p = 0.034).
Conclusions
PD-L1 was more frequently expressed in LCs of the non-GCB subtype. Additionally, PD-L1 in LCs may predict shorter PFS time. D-IHC staining for PD-L1/PAX5 is a feasible method to assess PD-L1 expression on LCs of DLBCL, NOS patients and can be used to identify patients who may benefit from targeted immunotherapy with checkpoint inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cytopathology, Institute of Oncology Ljubljana, Ljubljana, Slovenia.
- Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
- Department of Pathology, Institute of Oncology Ljubljana, Ljubljana, Slovenia.
- Faculty of Medicine, University of Maribor, Maribor, Slovenia.
- Department of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia.
Zitieren
APA
Slak, T. C., Miceska, S., Gasljevic, G., Boltezar, L., & Kloboves-Prevodnik, V. (2024). The prognostic significance of programmed cell death protein 1 and its ligand on lymphoma cells and tumor-immune cells in diffuse large B-cell lymphoma, not otherwise specified. Radiology and Oncology, 58(1), 99-109. https://doi.org/10.2478/raon-2024-0010
Vancouver
Slak TC, Miceska S, Gasljevic G, Boltezar L, Kloboves-Prevodnik V. The prognostic significance of programmed cell death protein 1 and its ligand on lymphoma cells and tumor-immune cells in diffuse large B-cell lymphoma, not otherwise specified. Radiology and Oncology. 2024;58(1):99-109. doi:10.2478/raon-2024-0010
BibTeX
@article{Slak2024,
author = {Slak, Teja Cas and Miceska, Simona and Gasljevic, Gorana and Boltezar, Lucka and Kloboves-Prevodnik, Veronika},
title = {The prognostic significance of programmed cell death protein 1 and its ligand on lymphoma cells and tumor-immune cells in diffuse large B-cell lymphoma, not otherwise specified},
journal = {Radiology and Oncology},
year = {2024},
volume = {58},
number = {1},
pages = {99--109},
doi = {10.2478/raon-2024-0010}
}
EUVIMED